World Diabetes Day is to be held on Nov. 14 and President Obama recently proclaimed November to be National Diabetes Month.
Technological advances that could improve diabetes control in the future made the news in the past month.
In the past month, a new meta-analysis compared metformin to other diabetes drugs, and the FDA expanded metformin's indications in patients with reduced kidney function.
The differences in outcomes between men and women with diabetes were the focus of a scientific statement from the American Heart Association and a study from Diabetologia, both published this month.
The prevalence and treatment of diabetes complications affecting the eye were analyzed by multiple studies published in the past month.
Two recent studies analyzed the effects of exercise on glycemic control in patients with type 2 diabetes or impaired glucose tolerance.
Two recent studies and FDA approval of the first “artificial pancreas” highlight new technological advances in type 1 diabetes care.
Three studies published in December looked at hypoglycemia, focusing on rates of severe hypoglycemia in the U.S., patients at high risk for hypoglycemia, and potential use of intranasal glucagon to treat the condition.
The effects of lifestyle interventions on patients with diabetes were analyzed by several recent studies.
The American Association of Clinical Endocrinologists and the American College of Endocrinology updated their algorithm for treatment of type 2 diabetes, while the American Diabetes Association released a position statement on management of diabetes